Objectives: 1.Access to Affordable Medicines 2. Medicines Safety, Added Therapeutic Value and Responsible Use 3. Democratisation of Medicines Policy
Activities:
1: Seek policy support from the Governments of Member States for alternative models of biomedical innovation—delinking R&D costs from the final price of a given medicine—as one component of improving access to currently unaffordable medicines
2: Promote the use of public-health sensitive IP management tools and TRIPS flexibilities in the EU to secure affordable access to medicines and ensure the sustainability of health systems
3: Seek public and high-level government support for initiatives that improve public access to clinical trial data and data on risk biases, and that enhance medicines’ pricing and reimbursement policies that contribute to sustainable health systems
4: Advocate for improved marketing authorisation procedures
5: Continue to engage new cohorts of medical students on the need to respond critically to pharmaceutical promotion, expanding our influence to research facilities and teaching staff
6: Monitor, contribute and react to emerging and ongoing EU policy developments and issue communication and policy materials related to HAI’s areas of expertise
7: Facilitate knowledge exchange on HAI’s areas of expertise to civil society and to new MEPs through the dissemination of recommendations related to EU medicines policy, engagement in meetings and events
8: Strengthen the HAI Europe Association of members to ensure that civil society’s voice is well represented in medicines policy discussions
9: Ensure continuation and transparency of HAI’s work and expand donor relations
We expect to reach over 1000 policy-makers, civil society representatives and members of the research community in the EU through our online and in-person advocacy efforts in 2020. We will produce over 60 outputs in line with the 16 deliverables outlined in our proposal.


Against the epidemiogical background and evidence that was described in the FPA2018 – 2021, in 2020, AIDS Action Europe (AAE) will continue the work under the three objectives
1. AAE contributes effectively to the HIV, TB and hepatitis response in Europe
2. AAE provides platforms to communicate and facilitate collaboration, networking, and linking and learning
3. Continuous improvement of network collaboration through governance and internal management.
As a comprehensive NGO network of 421 NGOs, national networks, AIDS service organisations, and community based groups in 47 countries in the WHO European Region, AAE will implement its work programme, i.e. with regard to Objective I, to serve as the secretariat to the EU CSF, to monitor and contribute to policy developments, to coordinate the European HIV Legal Forum, and advocate for CS concerns. Objective 2 comprises improved bilingual communication and exchange, intensified social media communication, dissemination of 3rd health programme information and tools, support of national and regional affordability advocacy efforts and provision of capacity building activities. Eventually, objective III includes ensuring topic-related sub-network cooperation, overall governance by the AAE Steering Committee and implementation, monitoring, evaluation, follow-up and fundraising for the work programme.
Herewith we will continue focusing on the following six core thematic areas identified by our members and partners:
- Community based voluntary counselling and testing
- Affordability of medicines
- Tackling legal barriers in the response to HIV, TB and hepatitis
- Criminalisation of HIV non-disclosure, exposure and transmission
- Sexual and reproductive health and rights
- Tackling stigma and discrimination



The Association of European Cancer Leagues (ECL) provides a unique platform as the only organisation with the mission of uniting at the European level, national and regional cancer leagues to achieve a cancer-free Europe. In coherence with the FPA 2018-2021, this SGA focuses on the core activities to be implemented in 2020 in respect of the following strategic objectives:

1) Informing policy to ensure cancer control remains high on the political agenda;
2) Promoting the European Code Against Cancer (ECAC) as the essential tool for cancer prevention;
3) Supporting leagues in the implementation of the Council Recommendation on Cancer Screening;
4) Uniting leagues to advocate for equal access to treatment, support, and rehabilitation for cancer patients;
5) Advocating for the European Guide for quality improvement in cancer control to be mainstreamed in national cancer plans.

These objectives will be achieved by several actions, including:

- Organisation of the 8th European Conference on Tobacco or Health and publication of the latest Tobacco Control Scale report including data from 38 countries in the European region;
- Implementing the MEPs against Cancer (MAC) European elections manifesto through coordinated actions of the group, supporting four structured meetings of the group;
- Publishing the final report of the systematic evaluation of impact of the European Code against Cancer and informing policymakers and the scientific community of results;
- Enhancing the ECL Youth Ambassadors programme to reach at least 40 European Countries and all EU member states in 2020;
- Supporting the roadmap towards a 3rd implementation report on cancer screening in the EU;
- Publication by the Patient Support Working Group of new guidance and training at the national level to address cancer in the workplace;
- Continuation of the advocacy work of the ECL Access to Medicines Task Force implementing the 2018 'Let's Talk Access' White Paper on Equal Access to Medicines.
